Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.7.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Cash flows from operating activities:    
Net loss $ (3,929) $ (14,716)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 25 305
Gain on sale of property and equipment (21) (51)
Stock-based compensation expense 919 1,645
Change in common stock warrant fair value (249) 626
Changes in operating assets and liabilities:    
Collaboration receivable/payable (129) 970
Prepaid expenses and other assets 530 1,305
Accounts payable (503) 2,351
Accrued clinical and development expenses (531) (4,737)
Accrued liabilities 1,027 (2,653)
Deferred rent (36) (44)
Net cash used in operating activities (2,897) (14,999)
Cash flows from investing activities:    
Issuance of promissory notes to Molecular Templates, Inc. (4,000) 0
Purchases of marketable securities (299) (13,454)
Proceeds from sale of property and equipment 100 61
Proceeds from maturities of marketable securities 13,006 31,192
Net cash provided by investing activities 8,807 17,799
Cash flows from financing activities:    
Proceeds from issuance of common stock and warrants 7 13
Net cash provided by financing activities 7 13
Net increase in cash and cash equivalents 5,917 2,813
Cash and cash equivalents, beginning of period 10,551 9,589
Cash and cash equivalents, end of period $ 16,468 $ 12,402